Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lipocine Inc (Lipocine) is a biopharmaceutical company that develops products for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men and women. The company’s pipeline products include LPCN 1154 which treats Postpartum depression; LPCN 2201 targets major depressive disorder; LPCN 2203 for essential tremor; LPCN 2101 treats drug resistant epilepsy; TLANDO for testosterone replacement therapy; LPCN 1148 which targets liver cirrhosis; LPCN 2401 treats obesity management -adjunct to GLP-1; and LPCN 1107 for prevention of preterm birth. It collaborates with pharmaceutical companies. Lipocine is headquartered in Salt Lake City, Utah, the US.
Headquarters
United States of America
Address
675 S Arapeen Dr Ste 202, Salt Lake City, Utah, 84108-1295
Website
www.lipocine.com
Telephone
1 801 9947383
No of Employees
14
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LPCN (NASD)
Revenue (2024)
$2.0M
-82.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-115399.5%
(2024 vs 2023)
Market Cap*
$17.4M
Net Profit Margin (2024)
XYZ
-695,885.7%
(2024 vs 2023)
* As of and is in US$
Lipocine Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| LPCN 1154: Postpartum Depression | TLANDO |
| LPCN 2201: Major Depressive Disorder | |
| LPCN 2203: Essential Tremor | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Lipocine Inc | Cumberland Pharmaceuticals Inc | Acumen Pharmaceuticals Inc | ContraFect Corp | Dicerna Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Salt Lake City | Nashville | Newton | Yonkers | Lexington |
| State/Province | Utah | Tennessee | Massachusetts | New York | Missouri |
| No. of Employees | 14 | 93 | 60 | 23 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard Dana Ono, Ph.D | Chairman | Executive Board | 2022 | 73 |
| Mahesh V. Patel, Ph.D | Chief Executive Officer; Director; President | Executive Board | 1997 | 69 |
| Krista Fogarty | Controller - Corporate; Principal Accounting Officer | Senior Management | 2022 | 59 |
| Nachiappan Chidambaram, Ph.D. | Senior Vice President - Research and Development | Senior Management | 2022 | 57 |
| Anthony DelConte, M.D. | Chief Medical Director | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer